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Burden of illness imposed by severe sepsis in Switzerland
Abstract
OBJECTIVE: This study aims to determine the burden of illness imposed by severe sepsis in
Switzerland by evaluating the direct and indirect patient-related costs for critically ill patients with
severe sepsis. METHODS: In order to estimate the direct costs a retrospective analysis was undertaken
using records from 61 adult patients treated in three intensive care units (ICUs) in three different
University hospitals in Switzerland, in 2001. Resource use was determined by a bottom up approach and
valued using centre-specific unit costs for medication, nutrition, blood products, disposables and official
tariffs for laboratory and microbiology analysis, diagnostic services, and clinical procedures. By adding
centre-specific personnel and basic bed (hotel) costs total direct costs in the ICU were calculated.
Indirect costs resulting from unfitness for work, early retirement, and premature death were calculated
using official Swiss statistics for the years 1998-2000. RESULTS: The mean total direct costs for a
severely septic patient are CHF 41,790 (+/- 33,222 CHF) or CHF 3244 (+/- 757 CHF) per day.
Nonsurvivors cause significantly higher costs than survivors (CHF 45,956 vs. CHF 37,759, p <0.001).
The total intensive care costs in Switzerland due to severe sepsis amount to CHF 146-355 million.
Indirect costs were estimated to range from CHF 347 to 844 million (predominantly due to premature
death). Consequently the burden of illness of severe sepsis can be estimated to range from CHF 493 to
1199 million per year in Switzerland (1 CHF = 0.662 Euro in 2001). CONCLUSION: Patients suffering
from severe sepsis in Switzerland have a high mortality rate and spend a prolonged time in the ICU,
leading to high direct and indirect costs. Particularly productivity losses due to premature death
represent a considerable burden to the Swiss society.
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Increasing pressure on health care budgets
worldwide emphasizes the need to address eco-
nomic implications of new services and therapies.
However, economic studies are still rarely found.
Due to differences in healthcare systems economic
questions need to be dealt with on a country-by-
country basis. These differences prevent an easy
application and adaptation of foreign findings to
the particular country of interest. Sepsis is one of
the disease areas that lately moved into medical so-
ciety’s focus because of its high mortality rate and
the ongoing search for effective drug therapies.
This general interest was recently increased by the
publication of the PROWESS trial [1], which
showed improved survival of severe sepsis patients
treated with drotrecogin alfa (activated). The in-
troduction of this new drug on the market certainly
raises cost related questions as new promising in-
ventions do not tend to be cheap. Additionally, sep-
sis is a disease generally treated in intensive care
units, a fact which per se already indicates a rather
high cost level. However, a fair discussion on a new
therapy cannot be started without knowledge of
the epidemiological and economic background.
Although sepsis is a well-documented disease
process regarding history, incidence and risk fac-
tors, information relating to the actual costs asso-
ciated with sepsis is rare. This fact may be related
to the general difficulties in undertaking cost of
disease studies in intensive care units based on in-
Objective: This study aims to determine the
burden of illness imposed by severe sepsis in
Switzerland by evaluating the direct and indirect
patient-related costs for critically ill patients with
severe sepsis.
Methods: In order to estimate the direct costs a
retrospective analysis was undertaken using
records from 61 adult patients treated in three in-
tensive care units (ICUs) in three different Uni-
versity hospitals in Switzerland, in 2001. Resource
use was determined by a bottom up approach and
valued using centre-specific unit costs for medica-
tion, nutrition, blood products, disposables and
official tariffs for laboratory and microbiology
analysis, diagnostic services, and clinical proce-
dures. By adding centre-specific personnel and
basic bed (hotel) costs total direct costs in the ICU
were calculated. Indirect costs resulting from un-
fitness for work, early retirement, and premature
death were calculated using official Swiss statistics
for the years 1998–2000.
Results: The mean total direct costs for a se-
verely septic patient are CHF 41790 (± 33222
CHF) or CHF 3244 (± 757 CHF) per day. Non-
survivors cause significantly higher costs than sur-
vivors (CHF 45956 vs. CHF 37759, p <0.001).
The total intensive care costs in Switzerland due
to severe sepsis amount to CHF 146–355 million.
Indirect costs were estimated to range from CHF
347 to 844 million (predominantly due to prema-
ture death). Consequently the burden of illness 
of severe sepsis can be estimated to range from
CHF 493 to 1199 million per year in Switzerland
(1 CHF = 0.662 Euro in 2001). 
Conclusion: Patients suffering from severe sep-
sis in Switzerland have a high mortality rate and
spend a prolonged time in the ICU, leading to high
direct and indirect costs. Particularly productivity
losses due to premature death represent a consid-
erable burden to the Swiss society.
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Introduction
adequate documentation of intensive care unit
(ICU) costs [2] and a lack of standardised models
to determine costs [3]. However, currently there
have been several publications on the cost of se-
vere sepsis in various countries [4–7], often using
a combination of methods (bottom-up, top-down
approaches for direct costs and calculations based
on statistical information for indirect costs). We
were interested to obtain specific information re-
garding the cost of illness of sepsis in Switzerland.
The aim of the present study was to investigate the
incidence of severe sepsis in Switzerland and to de-
termine its burden of illness based on the disease
related direct and indirect costs applying the soci-
etal point of view. 
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Material and methods
Knowledge of the incidence of severe sepsis is manda-
tory in order to calculate the burden of illness. Epidemi-
ological data was generated based on three different ap-
proaches. The first approach used literature and other
sources (unpublished data, expert opinion, etc.) to get first
estimates. A second approach projected mortality data
given by the Federal Statistical Office of Switzerland to
calculate the incidence, including not only the ICD-10
codes (International Classification of Diseases, Edition
10) of sepsis but also some organ failures most certainly
due to sepsis. In a third approach severe sepsis cases were
estimated based on the diagnosed disease of hospitalised
patients [8]. However, patients included were not only de-
clared sepsis cases but also patients with a disease most cer-
tainly leading to sepsis (certain percentages of these). The
combination of these three approaches yielded a range of
severe sepsis cases. The real number of cases most cer-
tainly lies within this incidence range.
To calculate the total costs associated with a specific
medical illness or condition, health economic research
generally differentiates three categories: direct costs, in-
direct costs, and intangible costs. Direct costs cover the
actual costs of services provided, including hospitalisation
costs, diagnostic tests, procedures, and medications. Indi-
rect costs quantify the estimated loss of income as the re-
sult of illness and death. Intangible costs include the non-
quantifiable costs associated with physical and emotional
pain and suffering. In order to estimate the burden of ill-
ness of severe sepsis in Switzerland both direct and indi-
rect costs have to be analysed. Resource use (i.e. the type
and frequency of goods and services rendered to the pa-
tient) and the monetary value (prices and unit costs) for
each type of these variables were used to estimate the di-
rect cost of severely septic patients. Data on the resource
use of severely septic patients in the ICU was collected by
means of a retrospective chart analysis using patient
records from three ICUs in the university hospitals of
Basle, Geneva, and Zurich. The study was approved by the
Ethics Committee of the hospital where required. Ran-
domly selected records of 61 adult patients suffering from
severe sepsis (defined according the ACCP/SCCM crite-
ria [9]), with a length of stay >24 h in the year 2001 were
evaluated. The chosen patient number represents about
1% of the estimated annual total number of severe sepsis
cases in Switzerland. Dosage and frequency of previously
defined healthcare goods and services (table 1) were as-
sessed for each patient over the whole length of stay in the
ICU and additionally some basic patient data such as age
and sex, data about length of ICU stay and length of treat-
ment, as well as data about ICU outcome (survivors or
non-survivors) and infection (on ICU admission and/or
acquired in ICU). All data was compiled in a database (MS
Access 2000). 
The assessed resources were valued with centre spe-
cific costs gathered by clinical experts and pharmacists
from the hospitals involved. Hospital purchasing prices
were applied to medication, consumables, nutrition, and
blood products. Staff costs per day of care were calculated
by dividing the summarised gross income from nurses and
physicians of the specific ICU with the days of care. Hotel
(basic bed) costs per day were derived from hospital ad-
ministrations. Some cost data could not be provided by the
three centres and was substituted with equivalent data
from additional Swiss centres including the Ospedale San
Giovanni in Bellinzona, Hôpital de Cadolles in Neuchâ-
tel, and Hôpital Régional in Sion. Routine and microbi-
ology laboratory as well as diagnostic services were cal-
culated using official tariffs (tax points multiplied with
cantonal tax point values) [10, 11]. Investment costs and
depreciation of ICU equipment was not taken into account.
We generally followed a conservative approach assessing
the resource use data. Therefore, we deliberately omitted
the resource use of the regular ward, because it was im-
possible to differentiate what was caused by severe sepsis
or an underlying disease. All cost data was turned into costs
per unit, added to the database and linked to the related
resources. Specific costs for each patient were calculated
by multiplying unit costs with the amount of resources
Medication (analgesics, sedatives, steroids, antibiotics, vasoactive drugs, muscle relaxants, etc.)*
Blood and blood products (fresh frozen plasma, platelets, etc.)*
Nutritional products (enteral and parenteral nutrition, vitamin and mineral supplements)*
Volume replacement (colloids, crystalloids, etc.)*
Laboratory tests (blood analysis, urine analysis, liver function tests, coagulation, etc.)
Microbiology (blood cultures, sputum, urine, antibiotic sensitivity pattern, etc.) 
Diagnostic services (X-ray, CT scan, etc.)**
Consumables (drainages, catheters, etc.)**
Staff services in ICU (physicians and nurses) 
Hotel costs for ICU
* are combined in cost group medication 
** are included in cost group consumables
Table 1
Assessed health care
goods and services.
used, and then all resource costs were summarised to total
cost per patient. Finally, the mean cost and standard devi-
ation was calculated. Costs per patient were multiplied
with the estimated incidence range to obtain the total di-
rect costs. Costs were calculated using 2001 prices. In 2001
the exchange rate to Euro was 1 CHF = 0.662.
Indirect costs were calculated using human produc-
tivity as substitute to estimate the effect of severe sepsis on
society in financial terms. This human capital approach is
commonly used since the human life and health cannot be
expressed directly by a given monetary value [12]. Indirect
costs include productivity loss (represented by lost in-
come) due to temporary morbidity (work absenteeism),
due to permanent morbidity (early retirement), and due
to mortality (premature death). To give productivity a
monetary value the official Swiss gross income from em-
ployment [13] was used since exact patient based income
data was not available. Apart from the calculations re-
garding productivity loss due to mortality no gender spe-
cific calculations were possible because information was
not detailed enough. The average productivity loss due to
temporary morbidity was calculated by multiplying the
statistical number of working days spent in hospital due to
severe sepsis [8] (data about stay at home after illness was
not available) with the gross income from employment per
day (official Swiss gross income from employment per
year divided by 220 working days = CHF 306.82 [13]) and
the estimated incidence range. The productivity loss due
to permanent morbidity was estimated by multiplying the
number of early retirements due to sepsis with the mean
working years lost and the gross income per year (CHF
67500 [13]). The mean working years lost were calculated
by deducting the average age of 51 years of patients in
working age in the assessed clinical data from the official
retirement age (65 years). To account for the fact that not
all early retirements start on January 1 and end on De-
cember 31, one year was subtracted from the average
number of life years lost per patient (half a year for the first
and another six month for the last year). Since no official
retirement figures were available on sepsis in Switzerland,
the low Austrian value from our previous study in Austria
[5] (0.16% in the year 2000, oral communication from the
“Hauptverband Sozialversicherungsträger”) was applied,
assuming that both countries are comparable with respect
to sepsis incidence, treatment and outcome. To obtain the
productivity loss due to mortality the number of deaths
was multiplied by the gross income per year [13] and by
the average work years lost per age group and gender based
on the assessed clinical data. The age and gender depend-
ing participation rate [13] was taken into account and again
one year was subtracted to account for the different re-
tirement dates as described above. Indirect costs due to
mortality and permanent morbidity were discounted with
5% [14]. “Saved” old-age pensions after early death or
given invalidity pensions do not enter in these direct cost
calculations because they do not represent a productivity
of the evaluated patient population.
The annual burden of illness imposed by severe sep-
sis in Switzerland was calculated by summing up the total
direct and indirect costs. 
Data analysis and cost calculations were done using
MS Access 2000, MS Excel 2000, and SPSS 11.0. Statisti-
cal analysis of cost differences in subgroups was performed
using the non-parametric bootstrapping method [15]
since traditional statistical methods to analyse the differ-
ence in costs are considered inappropriate [16, 17]. This
means that the observed data are treated as an empirical
probability distribution which is resampled with replace-
ment many times. Each resampling is used to provide an
estimate of the cost. The repeated estimates are used to
establish an empirical distribution with a sufficient sample
size, from which tests of hypothesis are constructed. Boot-
strapping was done within each subgroup using 1000
estimates for the analysis. Differences in length of stay
were tested statistically with the Mann-Whitney U test. 
A p-value of ≤0.05 was accepted as a significant difference. 
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Results
Epidemiological estimates show that between
5800 and 14 000 sepsis cases are treated in Switzer-
land per year. Assuming that 60% of all sepsis cases
evolve to severe sepsis [18, 19], the actual number
of severe sepsis cases per year probably lies be-
tween 3500 and 8500 cases.
A total of 61 severe sepsis patients requiring
786 days of intensive care were assessed. Patient
records were evaluated at three University hospi-
tals in Switzerland including the University hospi-
tal Zurich (27 patients), Geneva (19 patients), and
Basle (15 patients). The mean age of the patient
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Figure 1
Age distribution of
severely septic pa-
tients and percentage
of non-survivors.
population was 62 years (± 15.0). The majority of
patients, i.e. 57.4%, were male and 42.6% were fe-
male. An overall ICU mortality of 49.2% was ob-
served and an overall average length of stay (LOS)
in the ICU of 12.9 days (± 9.9). Survivors and non-
survivors showed almost the same LOS (12.6 [±
8.7] vs. 13.2 [± 11.2] days, p = 0.897). No relation
between mortality and age (figure 1) or mortality
and LOS (figure 2) was found, which may be ex-
plained by the small sample size.
The mean total direct cost per severely septic
patient amounted to CHF 41790 (± 33222) or
CHF 3244 (± 757) per day. The cost per severely
septic patient included medication, routine labo-
ratory testing, microbiology, consumables, hotel
and staff costs (table 2). Half of the costs are due
to staff, 19% to drugs and related goods (fluids,
blood products, nutrition etc.), and 9% are hotel
costs. Non-survivors cause higher mean costs per
patient than survivors (CHF 45956 (± 38464) vs.
CHF 37759 (± 27260), p <0.001). Non-survivors
have been found to spend almost the same number
of days in the ICU as survivors. Therefore differ-
ences in costs between survivors and non-survivors
can only be attributed to the higher resource use
of non-survivors compared to survivors. This is
also reflected by the finding that the mean cost per
day is higher in non-survivors (CHF 3481 vs. CHF
3001, p <0.001), which is mainly driven by higher
medication expenses (CHF 779 vs. 463, p <0.001).
Based on the incidence range of 3500 to 8500 se-
verely septic patients the total intensive care costs
lay between CHF 146 and 355 million (for details
see table 3).
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Distribution of length
of stay of severely
septic patients in ICU
and percentage of
non-survivors.
Components per patient per day
Medication 8020 622
Routine labs 3982 309
Microbiology 2030 158
Consumables 2726 212
Hotel costs 3803 295
Staff costs 21229 1648
Total mean direct costs 41790 3244
Table 2
Mean direct ICU cost
per severely septic
patient and per day
(in CHF).
Costs Low end of range High end of range 
(3500 patients) (8500 patients)
Direct costs
Medication 28.1 68.2
Routine laboratory tests 13.9 33.8
Microbiology 7.1 17.3
Consumables 9.5 23.2
Hotel costs 13.3 32.3
Staff costs 74.3 180.4
Total direct costs 146.2 355.2
Indirect costs
Productivity loss due to work absenteeism 12.6 30.7
Productivity loss due to early retirement 4.6 10.7
Productivity loss due to premature death 329.8 802.4
Total indirect costs 347.0 843.8
Total costs of severe sepsis in Switzerland (Mio) 493.2 1199.0
Table 3
Total costs of severe
sepsis in Switzerland
per year (Mio CHF).
Indirect costs due to severe sepsis in Switzer-
land were found to range from CHF 347 to 844
million. These costs are predominantly driven by
the high mortality rate of severe sepsis patients,
which accounts for a productivity loss ranging
from CHF 330 to 802 million. Work absenteeism
adds further productivity losses ranging from
CHF 12.6 to 30.7 million and early retirement
CHF 4.6 to 10.7 million. 
Combining direct and indirect costs, severe
sepsis imposes a yearly burden between CHF 493
and 1199 million to the Swiss society (table 3). 
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Discussion
Information about resource use and clinical
data in septic patients was collected by means of a
retrospective chart analysis. The used bottom up
approach allowed us to estimate costs for this spe-
cific patient group more accurately than would
have been possible with a top down approach.
However, such data collection is time consuming
and often hampered by the unavailability of cer-
tain cost data. Involving several hospitals allowed
us to substitute missing cost data with data from
one of the other centres, and had also a balancing
effect on centre specific cost variations. As a cer-
tain percentage of underreporting of used re-
sources in the patient files is plausible or a certain
amount of resources may have been overlooked
when assessing the health care goods used, we per-
formed a sensitivity analysis to check possible cost
implications when increasing the variable direct
costs by 10% or 20%. Even a 20% increase in costs
would not change results as they stay in the stan-
dard deviation range (± 33222 CHF) of the orig-
inally calculated mean per patient costs. There-
fore, the effect of some underreporting of resource
use does not significantly influence the final re-
sults. A slight underestimation of treatment costs
also results from the omission of regular ward stay
which we decided on due to a lack of exact infor-
mation. However, comparing the found mean ICU
LOS (12.9 days) with the average hospital LOS of
septic patients given in official statistics (15.8 days
[8]) suggests a stay on regular ward of about 3 days
per patient, which is not included in our calcula-
tions. On the other hand there might be a certain
overestimation of costs since this retrospective
study was carried out in university hospitals only.
However, in Switzerland all ICUs are clearly de-
fined, well equipped and adequately staffed units
which provide the same level of care [20] so that
resource use is comparable. Cost data were also
provided by non-University hospitals, which con-
tributed to a direct cost estimation representative
for Switzerland. Generally it can be stated that a
slight under- or overestimation of direct costs will
have relatively little effect, as they only represent
30% of the total costs.
In a burden of illness assessment indirect costs
must be included. However, estimating indirect
costs is a methodological problem as they cannot
be measured directly. We used the most commonly
applied approach although it has limitations re-
garding the economic assumptions it is based on
[12, 21, 22]. Indirect costs are influenced by the as-
sumed discount rate for future costs occurring
through productivity loss. We used the well ac-
cepted discount rate of 5% [14]. Applying no dis-
count rate or a higher rate of 10% would substan-
tially influence indirect costs (increase the indirect
cost range by about 60% and lower it by about 30%
respectively). Furthermore, a decreased long-term
survival of patients with severe sepsis might lead to
a further productivity loss. However, since litera-
ture reports are controversial regarding decreased
long term survival of severely septic patients, this
possibility was not taken into account. 
Average ICU mortality for severe sepsis was
49.2%, which was somewhat higher than the rates
found in Germany and Austria (respectively 36%
and 43.2% [5, 7]). Nonetheless, the rate lies within
the range of 30–50% reported in the literature [1,
23]. However, the mortality rate may have been bi-
ased by patient selection because in one centre sur-
viving patients had to give their consent before in-
clusion and not all of them did. This may have led
to an inclusion of non-survivors slightly above av-
erage. In addition, the observed mortality is based
only on a total of 61 patients and should therefore
be interpreted with caution. Apart from this, the
patient population evaluated does not significantly
differ in gender relation (57/43 compared with
58/42 and 66/34 in % male/female) or age (62 [±
15] vs. 58 [± 16.5] years in Germany and Austria)
from severely septic patient populations studied in
Germany and Austria [5, 7]. This suggests that the
evaluated patient population reflects the entire se-
verely septic patient population in Switzerland.
Comparing the Swiss cost data with those
from Germany and Austria offers comparable
findings [5, 7]. Non-survivors in all three countries
showed higher mean costs per day than survivors,
caused by higher resource use, i.e. higher medica-
tion costs. This fact results in equal or higher per
patient costs for non-survivors despite similar or
even shorter LOS in the ICU compared with sur-
vivors. Mean total ICU costs per patient are com-
parable to those found in Austria and are somewhat
higher than those found in Germany.
The mean direct costs of treating a septic pa-
tient were calculated to be CHF 3244 per day. This
corresponds to the total costs estimated for inten-
sive care patients with an extraordinary nursing re-
quirement (SGI category Ia) which is estimated to
be CHF 3142 [20] (adapted for the year 2001 based
on the consumer price index for hospital service
[24]). Based on the assumption that intensive care
accounts for 6–10% of total hospital expenses in
Switzerland [20], the total ICU costs of the year
2001 were CHF 662–1103 million [25]. Referring
to the previously described range of 3500–8500 pa-
tients with severe sepsis, the cost of severe sepsis
represents between 13% and 54% of the total ICU
costs in Switzerland.
Based on the study results we conclude that pa-
tients suffering from severe sepsis in Switzerland
have a relatively high mortality rate and spend an
average of 12.9 days in the ICU. They impose an
annual burden ranging from CHF 493 to 1199
million to the Swiss society. 
We thank Dr. R. Zürcher-Zenklusen, Hôpital de
Cadolles in Neuchâtel, Dr. A. Perren, Ospedale San Gio-
vanni in Bellinzona, and Dr. P. Eckert, Hôpital Régional
in Sion, Switzerland for supplying additional cost infor-
mation.
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